Vioxx risk could signify trouble in class

Nat Rev Drug Discov. 2004 Nov;3(11):899-901. doi: 10.1038/nrd1560.
No abstract available

Publication types

  • News

MeSH terms

  • Cardiovascular Diseases / etiology*
  • Clinical Trials as Topic
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / adverse effects*
  • Drug Industry*
  • Humans
  • Isoenzymes / metabolism
  • Lactones / adverse effects*
  • Membrane Proteins
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Risk
  • Sulfones

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Lactones
  • Membrane Proteins
  • Sulfones
  • rofecoxib
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases